Clinical Trial Update: Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer [Phase 2]

View source ↗

Summary

A Phase II clinical trial evaluating Abraxane (paclitaxel protein-bound particles) as front-line therapy for metastatic castration-resistant prostate cancer has…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)

Snippet

Sponsor: Kaiser Permanente | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED